Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective.
Therapy with angiotensin-converting enzyme (ACE) inhibitors was developed approximately 15 years ago as a novel therapeutic approach to hypertension. Although ACE inhibitor therapy was initially reserved for patients with severe hypertension, extensive clinical experience has broadened its use. These agents should now be considered as cornerstone therapy for patients with symptomatic heart failure and are of proved value in preventing the development of this syndrome. This article reviews the key studies that have documented the efficacy of ACE inhibitors in improving clinical outcome for patients with overt congestive heart failure, as well as for those with asymptomatic left ventricular dysfunction.
Pfeffer
M A
MA
Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D016019:Survival Analysis
D000806:Angiotensin-Converting Enzyme Inhibitors